Our targeted, small molecule therapies are designed to address treatment-resistance in cancer.
Working to deliver best-in-class pan-variant tyrosine kinase inhibitors to cancer patients.
We are developing a pipeline of TKIs designed to inhibit all major cancer-causing and drug resistance mutations in clinically significant tyrosine kinase targets.
View our latest news.
Nov 03, 2022
Oct 26, 2022